Compare AIDX & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIDX | EQ |
|---|---|---|
| Founded | N/A | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precision Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.8M | 64.5M |
| IPO Year | N/A | 2018 |
| Metric | AIDX | EQ |
|---|---|---|
| Price | $1.92 | $2.14 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.50 |
| AVG Volume (30 Days) | 280.5K | ★ 559.9K |
| Earning Date | N/A | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.47 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,095,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 13.89 |
| 52 Week Low | $1.87 | $0.29 |
| 52 Week High | $14.09 | $2.70 |
| Indicator | AIDX | EQ |
|---|---|---|
| Relative Strength Index (RSI) | 4.91 | 60.01 |
| Support Level | N/A | $1.22 |
| Resistance Level | $3.08 | $2.30 |
| Average True Range (ATR) | 0.44 | 0.23 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 7.05 | 45.89 |
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.